Oxytrol - (3.9MG/24HR; Film, Extended Release: Transdermal)

Generic Name	Oxybutynin	**Innovator**	Allergan
Dosage	3.9MG/24HR; Film, Extended Release: Transdermal	**Branded US Sales**	Less Than $1000 mn
Probable FTF	Less Than 5	**Known Para IV Filers**	Less Than 5
Other ANDA developers	None	**Tentative Approvals**	None
Final Approvals	None	**Generic Launches**	None
Indication	Indications for OXYTROL: Overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency.		
Complexities	Yes		

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.

Executive Summary

Please Contact contact@researchdelta.com to get Detailed Information.

Patent Status

Please Contact contact@researchdelta.com to get Detailed Information.

Launch Timelines and Competition

Please Contact contact@researchdelta.com to get Detailed Information.

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.